Scientists used IBM's R2 Heron quantum processor to predict the secondary protein structure of a 60-nucleotide-long mRNA ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Teams that bring a variety of experience and expertise can spot problems faster and arrive at more well-rounded, viable ...

Moderna's boom-and-bust cycle The COVID-19 pandemic brought about a transformation for Moderna, which quickly developed its mRNA vaccine with government funding and quick approvals in 2020.

HHS cancels $776M Moderna contract for avian flu vaccine, signaling a major change in vaccine research approach.

Wallace-Wells: You can see the same pattern applying to the management of disinformation, misinformation — which was ...

The Department of Health and Human Services is canceling the development of 22 mRNA vaccines, citing a lack of efficacy for preventing respiratory viruses like the flu and COVID-19. The department ...

If we've got vaccines for so many other viruses - including Covid-19, which emerged only a few years ago - why don't we have ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary Robert F. Kennedy, Jr.'s announcement ending federal support for mRNA ...